1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Non-opioid Pain Treatment: Global Markets to 2024

Non-opioid Pain Treatment: Global Markets to 2024

  • December 2019
  • 165 pages
  • ID: 5343383
  • Format: PDF
  • BCC Research


Table of Contents

Report Scope:
This report is designed to be a helpful business tool that will provide a thorough evaluation of the markets for pain management.The geographical scope of this study is global.

This study addresses acute versus chronic pain, treatments and regulatory issues facing healthcare workers. Also provided is detailed information based on product categories, use of products, forecasts and competitive analyses.

The report identifies five general product segments for Non-opioid treatment of pain -
- Medical cannabis treatments.
- Capsaicin-derived treatments.
- Menthol-containing treatments.
- Omega 3 fatty acid-containing treatments.
- Botulinum toxins.

Within the segment several sub-segments are discussed as they pertain to each product segment; diseases or disorders are the basis for these sub-segments, including -
- Arthritis.
- Cancer–brain, breast, colorectal, leukemia/lymphoma, melanoma, prostate, others.
- Dental.
- Epilepsy.
- Fibromyalgia.
- Migraine.
- Multiple sclerosis.
- Surgical.

A regional analysis of these product segments is also provided, including the specific countries listed below and including countries not listed as a “rest of the world” market.
- Argentina.
- Australia/New Zealand.
- Brazil.
- Canada.
- China.
- France.
- Germany.
- Italy.
- Japan.
- Mexico.
- Russia.
- Spain.
- United Kingdom.
- United States.

Each market segment provides detailed information based on product categories, product use, current market value and forecasts.

Not covered in the report are drugs or devices that are considered “conventional” in professional treatment guidelines that are due to either controversial issues such as those with medical cannabis or those that are not commonly prescribed or recommended due to a lack of clinical data, education or other factors.

Report Includes:

- 44 data tables and 19 additional tables
- An overview of the global market for Non-opioid pain treatments
- Analyses of global market trends, with data from 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024
- Description of products included in this market, and a detailed analysis of the markets and market opportunities
- Information on significant products categories, issues and trends, market influences, regulatory issues and other information affecting the pain management industry
- Briefing about major drivers and regional dynamics of the market and current trends within the industry
- Comprehensive profiles of major vendors in the market, including Allergan PLC, Canopy Growth Corp., Medical Marijuana Inc., Panag Pharma Inc., and Tilray

The global non-opioid pain treatment market, which focuses on alternative non-opioid treatments, reached a total market value of nearly REDACTED billion in 2018. The market is divided into five generalsegments for this report, including medical cannabis, capsaicin-derived treatments, menthol-containing treatments, omega-3 fatty acid-containing and botulinum toxins. Various findings specific to each segment are discussed below -

Medical cannabis
- Largest alternative non-opioid market segment, accounting for a REDACTED market share.
- The United States is the largest market for medical cannabis, accounting for REDACTED of global sales.
- The street cost of cannabis is the highest in Japan (it is illegal for all uses in Japan).

Medical cannabis is most often used to control pain in orthopedic and musculoskeletal conditions.Arthritis and fibromyalgia are the most common individual indications.

About REDACTED of sales are for this group o f indications.
- Increasing use in neuropathic pain has shown effectiveness.
- Growing number of medical cannabis clinical trial listings.

Capsaicin-derived treatments
- Smallest market segment, accounting for just 2% of the global non-opioid pain treatment market.

Menthol-containing treatments
- Second-largest alternative non-opioid market segment, accounting forREDACTED marke t share.
- Menthol-containing treatments have been shown to be effective in treating neuropathies.
- Increasing rate of diabetes and other conditions with high prevalence of neuropathies will fuel growth.
- Major market segment in Latin American pain treatment markets.

Omega-3 fatty acid-containing
- Accounts for 8% of the global non-opioid pain treatment market.
- Aging populations will be a strong driver for growth.
- Increasing orthopedic conditions and injuries will support growth.
- Major segment in Asia-Pacific pain treatment markets, accounting for REDACTED to REDACTED of non-opioid pain treatment sales in develo ped countries.

Botulinum toxins
- Accounts for REDACTED of the global non-opioid pain treatment m arket.
- Botox is the leading product in the segment and is marketed by Allergan.
- The U.S. market is the largest market due to the availability and reimbursement of Botox.
- Global push for education in alternative migraine treatments and awareness.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Nociceptin Receptor - Pipeline Review, H1 2020

  • $ 3500 - $ 2625 - Get 25% off now!
  • April 2020
  • 52 pages

Nociceptin Receptor - Pipeline Review, H1 2020 Summary Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) pipeline Target constitutes close to 16 molecules. Out ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on